Diabetic Peripheral Neuropathy (Investigational Adjunct)

Investigational adjunct for symptomatic diabetic peripheral neuropathy; glycemic control, foot care, and pharmacotherapy (duloxetine, pregabalin, gabapentin) remain evidence-based.

Tier C — InvestigationalInvestigacionalLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Resumen para el Paciente

¿Está esto autorizado por FDA para este uso?: Not FDA-cleared for diabetic peripheral neuropathy. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is investigational and is generally inadvisable because the risk profile in diabetic patients is uniquely unfavorable.
¿Qué evidencia existe?: Tier C (investigational). There are no published controlled trials for diabetic peripheral neuropathy. The only intervention with disease-modifying evidence is tight glycemic control (HbA1c target individualized). Symptom control is evidence-based: duloxetine, pregabalin, gabapentin, amitriptyline, and topical capsaicin or lidocaine - all with RCT support. Foot care (daily inspection, well-fitting footwear, podiatry follow-up, monofilament screening) is critical to prevent ulcer and amputation. Diabetic patients have impaired healing and high infection risk, which makes any skin-breaking procedure - including leech bites - dangerous.
Riesgos principales: Bleeding from the bite site for 6 to 24 hours after detachment
Slow or non-healing of the bite wound in diabetic skin
HIGH RISK of skin or, in particular, Aeromonas hydrophila infection - serious in diabetes
Risk of triggering a non-healing diabetic ulcer at the bite site
Cellulitis, deep tissue infection, or osteomyelitis from a contaminated bite
Risk of progression to limb-threatening infection (especially in patients with peripheral arterial disease)
Allergic reaction to leech saliva (uncommon)
Delay of evidence-based glycemic optimization and pharmacotherapy
Quién no debería considerar esto: Patients with any active diabetic foot ulcer, cellulitis, or osteomyelitis
Patients with peripheral arterial disease (ABI under 0.7) or absent pedal pulses
Patients with poorly controlled diabetes (HbA1c above 8.5 percent)
Patients with reduced protective sensation on monofilament testing (cannot reliably detect bite-site complications)
Patients on anticoagulants, with hemophilia, or with severe anemia
Patients with active retinopathy who cannot afford additional anemia risk
Patients with end-stage renal disease or significant immunosuppression
Qué preguntar a su clínico: What is my HbA1c, and have we optimized glycemic control first?
Have I had a foot exam, monofilament testing, and ABI to assess for peripheral arterial disease?
Have I tried evidence-based pharmacotherapy (duloxetine, pregabalin, gabapentin, amitriptyline)?
Have I tried topical capsaicin or lidocaine patches?
Why is leech therapy being considered given the high infection and non-healing risk in diabetes?
What is the Aeromonas-prevention protocol, and what is the fallback if infection develops?
Where exactly will leeches be placed - confirm NEVER on the foot, NEVER over an area with reduced sensation?
Cuándo buscar atención urgente: Any non-healing wound, ulcer, or persistent open bite site
Spreading redness, warmth, drainage, or pus at the bite site or anywhere on the foot
Fever, chills, or sudden worsening of glycemic control (possible deep infection)
Sudden severe foot pain, pallor, or coolness (possible critical limb ischemia)
Red streaks running up the leg from the bite site (lymphangitis)
Bleeding from the bite site lasting more than 24 hours
Hives, facial or throat swelling, or breathing difficulty

Qué NO significa esto

This is not FDA-cleared for diabetic peripheral neuropathy.
It does not improve glycemic control, the only intervention shown to slow DPN progression.
It does not replace duloxetine, pregabalin, or gabapentin for neuropathic pain - these have RCT support.
It is uniquely dangerous in diabetic patients: bleeding from a bite plus impaired healing plus high infection risk can precipitate ulcer or limb loss.
Most clinicians should decline; the risk-benefit ratio is unfavorable.

Referencias cruzadas de seguridad

Clinical Profile

Category: neurological
ICD-10: E11.40, E11.42, G62.9, G99.0
Safety tier: high

Evidence Summary

Diabetic peripheral neuropathy (DPN) is the most common diabetic microvascular complication, causing distal symmetric sensory loss and neuropathic pain. ADA evidence-based management includes optimal glycemic control, foot care education, screening, and pharmacotherapy with duloxetine, pregabalin, gabapentin, or amitriptyline for painful neuropathy. Topical capsaicin and lidocaine play adjunctive roles. No published controlled trials of hirudotherapy exist for DPN. Diabetic patients have heightened infection risk, impaired wound healing, and are often anticoagulated for cardiovascular indications, making the risk-benefit profile especially unfavorable. Distal foot placement is dangerous in this population because of compromised microcirculation and ulcer risk.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Detailed Trial Entries

2 trials indexed in the ASH RCT Library with full Study Profile, GRADE rating, and clinical implications:

Contraindications

Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
Hemophilia or other bleeding disorder
Severe anemia (Hb <10 g/dL)
Active bacteremia or sepsis
Known hypersensitivity to leech salivary proteins
Pregnancy (relative — first/third trimester)
Immunocompromised state with severe neutropenia
Active deep vein thrombosis (acute phase <2 weeks)
Critical limb ischemia (ABI <0.4)
Active diabetic foot ulcer or callus breakdown
Charcot foot or active osteomyelitis
HbA1c >8 percent (optimize glycemic control first)
Antiplatelet or anticoagulant therapy (most diabetic patients)
Distal foot placement (always contraindicated in DPN)
Peripheral arterial disease with ABI <0.9

Related Conditions

Cervical Radiculopathy

Off-label use with one RCT (Michalsen 2018) showing significant pain reduction at 7 days in cervical radiculopathy without surgical indication.

Lumbar Radiculopathy (Sciatica)

Off-label use with controlled trial evidence (n=80) showing leg pain and Oswestry score improvement at 4-12 weeks in non-surgical lumbar disc disease.

Migraine

Investigational use with case-series evidence for reduction of migraine frequency and intensity; mechanism plausible via reduction of cervico-cranial venous congestion.

Tension-Type Headache

Investigational use with small case series suggesting frequency reduction in chronic tension headache via reduction of pericranial muscle tension and venous congestion.